The specificity of the interaction between masitinib and dCK was next validated in vitro on three cell line lysates (HMC-1.1, HRT18 and Messa 10K (human ovarian sarcoma cell line)) by pull-down and western blotting, using the NH2-modified masitinib probe (Fig. 1c). This evidence concerns the gene DCK and ovarian sarcoma.